- Home
- REPL vs SANA Comparison
REPL vs SANA Comparison
Compare REPL & SANA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REPL
- SANA
- Stock Information
- Founded
- REPL 2015
- SANA 2018
- Country
- REPL United States
- SANA United States
- Employees
- REPL N/A
- SANA N/A
- Industry
- REPL Biotechnology: Pharmaceutical Preparations
- SANA Medicinal Chemicals and Botanical Products
- Sector
- REPL Health Care
- SANA Health Care
- Exchange
- REPL Nasdaq
- SANA Nasdaq
- Market Cap
- REPL 578.4M
- SANA 519.8M
- IPO Year
- REPL 2018
- SANA 2021
- Fundamental
- Price
- REPL $7.71
- SANA $1.82
- Analyst Decision
- REPL Strong Buy
- SANA Strong Buy
- Analyst Count
- REPL 6
- SANA 5
- Target Price
- REPL $20.00
- SANA $9.50
- AVG Volume (30 Days)
- REPL 1.1M
- SANA 2.4M
- Earning Date
- REPL 05-19-2025
- SANA 05-08-2025
- Dividend Yield
- REPL N/A
- SANA N/A
- EPS Growth
- REPL N/A
- SANA N/A
- EPS
- REPL N/A
- SANA N/A
- Revenue
- REPL N/A
- SANA N/A
- Revenue This Year
- REPL $31.16
- SANA N/A
- Revenue Next Year
- REPL N/A
- SANA N/A
- P/E Ratio
- REPL N/A
- SANA N/A
- Revenue Growth
- REPL N/A
- SANA N/A
- 52 Week Low
- REPL $4.92
- SANA $1.26
- 52 Week High
- REPL $17.00
- SANA $9.49
- Technical
- Relative Strength Index (RSI)
- REPL 39.21
- SANA 49.90
- Support Level
- REPL $6.93
- SANA $1.67
- Resistance Level
- REPL $10.30
- SANA $2.04
- Average True Range (ATR)
- REPL 0.73
- SANA 0.16
- MACD
- REPL -0.07
- SANA 0.03
- Stochastic Oscillator
- REPL 23.15
- SANA 49.41
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.
About SANA Sana Biotechnology Inc.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.